Article Information
History
- March 25, 2021.
Copyright
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission.
Author Information
- Xavier Solanich, MD1,†,*,#,
- Gardenia Vargas-Parra, MD, PhD2,3,†,
- Caspar I. van der Made4,5,6,7,†,
- Annet Simons4,
- Janneke Schuurs-Hoeijmakers4,
- Arnau Antolí, MD1,
- Jesús del Valle, PhD2,3,
- Gemma Rocamora-Blanch, MD1,
- Fernando Setién, PhD8,
- Manel Esteller, MD, PhD3,8,9,10,
- Antoni Riera-Mestre, MD, PhD1,11,
- Joan Sabater-Riera, MD, PhD12,
- Gabriel Capellá, MD, PhD2,3,
- Frank L. van de Veerdonk5,6,7,
- Ben van der Hoven13,
- Xavier Corbella, MD, PhD1,14,
- Alexander Hoischen4,5,6,7,*,# and
- Conxi Lázaro, PhD2,3,*,#
- 1Department of Medicina Interna. Hospital Universitari de Bellvitge - IDIBELL. L’Hospitalet de Llobregat, Barcelona, Spain
- 2Hereditary Cancer Program, Catalan Institute of Oncology, Program in Molecular Mechanisms and Experimental Therapy in Oncology (Oncobell), IDIBELL, L’Hospitalet de Llobregat, Barcelona, Spain
- 3Centro de Investigación Biomédica en Red de Cáncer (CIBERONC), Spain
- 4Department of Human Genetics, Radboud University Medical Center, Nijmegen, the Netherlands
- 5Radboud University Medical Center Center for Infectious Diseases (RCI), Department of Internal Medicine, Radboud University Medical Center, Nijmegen, the Netherlands
- 6Radboud Institute for Molecular Life Sciences, Radboud University Medical Center, Nijmegen, the Netherlands
- 7Radboud Expertise Center for Immunodeficiency and Autoinflammation and Radboud Center for Infectious Disease (RCI), Radboud University Medical Center, Nijmegen, the Netherlands
- 8Josep Carreras Leukaemia Research Institute (IJC), Badalona, Barcelona, Spain
- 9Institucio Catalana de Recerca i Estudis Avançats (ICREA), Barcelona, Spain
- 10Physiological Sciences Department, School of Medicine and Health Sciences, University of Barcelona (UB), Barcelona, Spain
- 11Faculty of Medicine and Health Sciences, Universitat de Barcelona, Barcelona, Spain
- 12Department of intensive Care. Hospital Universitari de Bellvitge - IDIBELL. L’Hospitalet de Llobregat, Barcelona, Spain
- 13Department of Intensive Care, Erasmus MC, Rotterdam, the Netherlands
- 14School of Medicine, Universitat Internacional de Catalunya, Barcelona, Spain
- ↵#CORRESPONDING AUTHOR Xavier Solanich, MD, Department of Internal Medicine, Bellvitge University Hospital, Bellvitge Biomedical Research Institute (IDIBELL), Feixa Llarga sn. 08907 L’Hospitalet de Llobregat (Barcelona), Spain, Phone: 0034 96 260 2324, Fax: (+34) 93 260 7967, Email: xsolanich{at}bellvitgehospital.cat, Alexander Hoischen, Departments of Human Genetics and Internal Medicine, Radboud University Medical Center, Nijmegen, the Netherlands, Phone: (+31) 24 3619639, Email: Alexander.Hoischen{at}radboudumc.nl, Conxi Lázaro, Ph.D., Hereditary Cancer Program, Catalan Institute of Oncology, IDIBELL and CIBERONC., Av. Gran Via 199-203. 08908 Hospitalet de Llobregat (Barcelona), Spain. Phone: (+34) 93 2607145, E-mail: clazaro{at}iconcologia.net
↵† These authors contributed equally and should be considered first co-authors
Posted March 25, 2021.
Genetic screening for TLR7 variants in young and previously healthy men with severe COVID-19: a case series
